

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

STEADYMED LTD.,

Petitioner,

v.

UNITED THERAPEUTICS CORPORATION

Patent Owner.

Case IPR2016-00006

Patent No. 8,497,393 B2

---

**DECLARATION OF BORIS LEVINE UNDER 37 C.F.R. § 42.63(B)**

I, Boris Levine, hereby declare:

1. I am the President, owner, and chief Japanese translator at Technical Language Services, Inc. I am the head of its Far Eastern Languages Department and am in charge of its Japanese-language-training program. Technical Language Services, Inc., an ISO 9001-2008 certified translation company incorporated in the

state of Nevada, provides translation and interpretation services to companies in the United States and around the world. Under my guidance, every month our company delivers hundreds of written translations from Japanese to English to the World Intellectual Property Organization in Geneva and numerous intellectual property law firms in Japan.

2. I am fluent in the Japanese and English languages.
3. I have been translating Japanese patents since 1978, and have been working as a Japanese translator in the United States since 1990.
4. Prior to emigrating to the United States, I was employed in the Former Soviet Union at GIPRONICKEL Research Institute in Saint Petersburg, where my role was to translate technical scientific papers from Japanese to Russian. I was a translator there for 11 years.
5. I requested that Technical Language Services employee James Dowdle, one of our company's translators who is fluent in the Japanese and English languages, provide a translation that is a true and accurate translation of the Japanese Patent Application No. 56-122328A (Kawakami), Crystalline Amine Salt of Methanoprostacyclin Derivative, Manufacturing Method Thereof, and Purifying Method Thereof.

6. Mr. Dowdle is a Japanese-to-English translator who is competent to translate this patent application and who has been receiving continuous training as a Japanese translator since joining the company in 2012.


7. I personally checked, using my expertise in Japanese and English, that the English translation that Mr. Dowdle created is a true and accurate translation of the Japanese Patent Application No. 56-122328A (Kawakami), Crystalline Amine Salt of Methanoprostacyclin Derivative, Manufacturing Method Thereof, and Purifying Method Thereof, and provided a declaration dated September 22, 2015, to the Board. (Ex. 1011).

8. It is the practice in our industry that the relevant company officer, not the original translator, provides the certification that the translation is true and accurate. That is why I, and not Mr. Dowdle, provided the declaration of September 22, 2015.

9. I again confirm, based on my personal knowledge of the Japanese and English languages, that the translation my ISO-certified company provided at Ex. 1007 is a true and accurate translation of the Japanese Patent Application No. 56-122328A (Kawakami), Crystalline Amine Salt of Methanoprostacyclin Derivative, Manufacturing Method Thereof, and Purifying Method Thereof.

I hereby declare that all statements made herein are of my own personal knowledge; all statements made on information and belief are believed to be true;

and all statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.



Boris Levine  
President  
Technical Language Services, Inc.  
April 14, 2016

## CERTIFICATE OF SERVICE

The undersigned certifies that a copy of the attached DECLARATION OF BORIS LEVINE UNDER 37 C.F.R. § 42.63(B), was served via electronic mail to the following:

Stephen B. Maebius  
George Quillin  
FOLEY & LARDNER LLP  
[UT393-IPR@foley.com](mailto:UT393-IPR@foley.com)

Shaun R. Snader  
UNITED THERAPEUTICS CORP.  
[ssnader@unither.com](mailto:ssnader@unither.com)

Douglas Carsten  
Richard Torczon  
Robert Delafield  
WILSON, SONSINI, GOODRICH & ROSATI  
[dcarsten@wsgr.com](mailto:dcarsten@wsgr.com)  
[rtorczon@wsgr.com](mailto:rtorczon@wsgr.com)  
[bdelafield@wsgr.com](mailto:bdelafield@wsgr.com)

Date: April 29, 2016

Respectfully submitted,

/s/ Stuart E. Pollack /  
Stuart E. Pollack, J.D., Ph.D.  
Reg. No. 43,862  
DLA Piper LLP (US)

/s/ Lisa A. Haile /  
Lisa A. Haile, J.D., Ph.D.  
Reg. No. 38,347  
DLA Piper LLP (US)